PRN — Profound Medical Cashflow Statement
0.000.00%
Last trade - 00:00- CA$345.57m
- CA$282.61m
- $16.10m
Annual cashflow statement for Profound Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -30.7 | -28.7 | -28.3 | -27.8 | -42.6 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.51 | 4.99 | 4.43 | 1.89 | 5.89 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.05 | -3.72 | 0.294 | 1.69 | -2.11 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -22.4 | -25.8 | -22.6 | -23.5 | -38.2 |
| Capital Expenditures | -0.593 | 0 | — | — | -0.242 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -0.593 | 0 | — | — | -0.242 |
| Financing Cash Flow Items | -0.099 | 7.12 | 0 | -4.89 | -1.02 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5.95 | 7.03 | 1.76 | 54.7 | 41.1 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -16.8 | -20.6 | -20.3 | 28.7 | 4.81 |